NeuroOne Medical Technologies Corporation (NASDAQ:NMTC - Get Free Report) insider David Wambeke bought 1,000,000 shares of the stock in a transaction on Sunday, March 1st. The stock was acquired at an average cost of $0.67 per share, for a total transaction of $670,000.00. Following the acquisition, the insider directly owned 1,000,000 shares in the company, valued at approximately $670,000. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
NeuroOne Medical Technologies Stock Up 21.4%
Shares of NMTC stock opened at $0.81 on Wednesday. NeuroOne Medical Technologies Corporation has a 12 month low of $0.40 and a 12 month high of $1.16. The firm has a market cap of $40.93 million, a PE ratio of -4.76 and a beta of 0.74. The stock has a 50 day moving average of $0.81 and a 200-day moving average of $0.79.
NeuroOne Medical Technologies (NASDAQ:NMTC - Get Free Report) last announced its quarterly earnings data on Tuesday, February 17th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.01. The business had revenue of $2.89 million for the quarter, compared to the consensus estimate of $2.47 million. NeuroOne Medical Technologies had a negative net margin of 78.34% and a negative return on equity of 119.92%.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on NMTC. Zacks Research upgraded shares of NeuroOne Medical Technologies from a "hold" rating to a "strong-buy" rating in a research note on Monday, January 5th. JonesTrading began coverage on NeuroOne Medical Technologies in a report on Monday. They issued a "buy" rating and a $1.50 price target for the company. Finally, Wall Street Zen upgraded NeuroOne Medical Technologies to a "sell" rating in a research report on Saturday, February 21st. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $1.98.
Check Out Our Latest Research Report on NMTC
Institutional Trading of NeuroOne Medical Technologies
Several institutional investors have recently made changes to their positions in NMTC. Focus Financial Network Inc. bought a new stake in NeuroOne Medical Technologies in the third quarter valued at about $31,000. Warberg Asset Management LLC acquired a new stake in NeuroOne Medical Technologies during the second quarter valued at approximately $27,000. Legato Capital Management LLC bought a new stake in shares of NeuroOne Medical Technologies in the 4th quarter valued at approximately $34,000. Squarepoint Ops LLC acquired a new position in shares of NeuroOne Medical Technologies in the 4th quarter worth approximately $36,000. Finally, Susquehanna International Group LLP acquired a new position in shares of NeuroOne Medical Technologies in the 3rd quarter worth approximately $47,000. 16.07% of the stock is currently owned by institutional investors and hedge funds.
About NeuroOne Medical Technologies
(
Get Free Report)
NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company's core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.
The company's flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
